Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Actelion
- Target Recruit Count
- 47
- Registration Number
- NCT04211272
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT04176978
- Locations
- 🇭🇰
Department of Medicine and Therapeutics, Hong Kong, Hong Kong
A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT04124003
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT04099732
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Investigation of the Gut Microbiome and Statin Response
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Sony Tuteja
- Target Recruit Count
- 62
- Registration Number
- NCT04098003
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04094519
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04092595
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 61
- Registration Number
- NCT04008186
- Locations
- 🇺🇸
Covance Clinical Research Unit (CRU) Inc., Dallas, Texas, United States
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03970798
- Locations
- 🇯🇵
Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
- Conditions
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT03954366
- Locations
- 🇵🇱
Zdrowie Kobiety Centrum Leczniczo-Rehabilitacyjne i Medycyny Pracy ATTIS Sp. z o.o., Zakład Onkologii Kobiecej, Warszawa, Poland
🇸🇰Summit Clinical Research s.r.o., Bratislava, Slovakia
🇭🇺PRA Magyarország Fázis I-es Klinikai Farmakológiai Vizsgálóhely FMC Dialízis Központ, II. em., Budapest, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.